AC Immune SA
ACIU- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001651625
No open-market purchases or sales by AC Immune SA insiders were filed in the last 90 days; 43 institutions reported holding it in 13F filings for Q2 2026, worth $75.2M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by AC Immune SA insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for AC Immune SA, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Zuegel Martin | Interim CEO | 71,408 | Jun 15, 2026 | 1 |
| Aguiar-Lucander Renee | Director | 51,136 | Jun 15, 2026 | 1 |
| Buetler Monika | Director | 71,656 | Jun 15, 2026 | 1 |
| June Carl Howard | Director | 67,556 | Jun 15, 2026 | 1 |
| Twyman Roy Ervin | Director | 92,556 | Jun 15, 2026 | 1 |
| Pfeifer Andrea | Chief Executive Officer | 3,820,288 | May 18, 2026 | 2 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 18, 2026 (view filing) | May 15 | 3 days | Pfeifer AndreaChief Executive Officer | SSaleCommon Share | −10.0K | $2.79 | −$27.9K | −0.3%3.82M after | 10b5-1 |
| Apr 16, 2026 (view filing) | Apr 15 | 1 day | Pfeifer AndreaChief Executive Officer | SSaleShare | −10.0K | $3.14 | −$31.4K | −0.3%3.83M after | Amended10b5-1 |